Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
We assumed an additive genetic model for each host and bacterial variant
Liang Y, et al
Potential side effects include: Water retention (especially early in the protocol) Mild joint discomfort or stiffness Temporary fatigue or lethargy Flushing or warmth at the injection site Headaches (typically mild and transient) Most side effects are dose-dependent and resolve with dosage adjustment
hospitalization required Maintenance of Remission: Immunomodulators (azathioprine, 6-MP, methotrexate) for steroid-dependent or frequently-relapsing disease Biologic monotherapy or combination therapy (biologic + immunomodulator) for moderate-to-severe disease Step-up or top-down approach based on disease severity, patient risk factors, and prior therapy Biologic Therapy Targets: TNF-: Infliximab (IV), adalimumab (SC), certolizumab pegol (SC) IL-12/23: Ustekinumab (IV induction, SC maintenance) Integrin: Vedolizumab (IV) IL-23: Risankizumab (IV induction, SC maintenance) JAK inhibition: Upadacitinib (oral) Surgical Management Surgery is indicated in approximately 7080% of patients with Crohns disease over their lifetime, per StatPearls
US$ 22.79
US$ 24.06
US$ 20.84
